Urine Biopsy Detects Biomarkers, Drug Targets in Prostate Cancer
Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.
Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.
Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.
Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
Urinary, bowel, sexual function, and quality of life among men with prostate cancer may vary depending on treatment type.
Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.
Men with low-risk prostate cancer who undergo open or robot-assisted radical prostatectomy may have favorable oncological outcomes.
Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.
In adjusted analyses, serum phosphorus levels independently predicted glucose disposal rate.